National Saudi Consensus Statement on the Management of Atopic Dermatitis (2021)

Fatani, Mohammad I.; Sheikh, Afaf Al; Alajlan, Mohammed Abdulaziz; Alharithy, Ruaa; Binamer, Yousef; Albarakati, Rayan G; Alenzi, Khalidah A.; Khardaly, Amr; Al-Omari, Bedor A.; Almudaiheem, Hajer; Al‐Jedai, Ahmed; Eshmawi, Maysa

doi:10.1007/s13555-022-00762-6

Cited by 7 publications

(19 citation statements)

References 115 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional tests also include those needed to exclude contraindications for the intended therapy. 13…”

Section: Agnosis a N D Base Li N E E X A M I Nationmentioning

confidence: 99%

“…The usual dose of cyclosporine in the treatment of alopecia areata varies from 3 to 5 mg/kg/day. 13 The dose of 5 mg/ kg/day should not be exceeded, because of the increased risk of nephrotoxicity. Lower doses (i.e.…”

Section: Cyclosporinementioning

confidence: 99%

“…32 It is usually used as a steroid-sparing agent. 13,19 The drug is usually started at a low dose of 0.5-1 mg/kg/day to reduce the risk of gastrointestinal problems. It is gradually titrated every 4-6 weeks, reaching the maximum dose rate of 2-3 mg/kg/day based on patient response and tolerance.…”

Section: Azathioprinementioning

confidence: 99%

“…Treatment duration with glucocorticosteroids should be limited if possible to reduce the risk of adverse events. 13,19 To minimize the risk of relapses, treatment should ideally be continued for at least 6-12 months after complete hair regrowth, 16,19 before a possible switch to maintenance therapy or discontinuation. Detailed standards for maintenance therapy are still to be established and defined after specific clinical trials.…”

Section: Treatment Duration and Follow-upmentioning

confidence: 99%

See 3 more Smart Citations

European expert consensus statement on the systemic treatment of alopecia areata

Rudnicka,

Arenbergerova,

Grimalt

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

Alopecia areata is an autoimmune form of non‐scarring hair loss. It is usually characterized by limited areas of hair loss. However, the disease may progress to complete scalp and body hair loss (alopecia totalis, alopecia universalis). In patients with alopecia areata hair loss significantly impacts the quality of life. Children and adolescents with alopecia areata often experience bullying, including physical aggression. The disease severity evaluation tools used in clinical practice are: the Severity of Alopecia Tool (SALT) score and the Alopecia Areata Scale (AAS). A SALT score equal to or greater than 20 constitutes a commonly accepted indication for systemic therapy in alopecia areata. When using the AAS, moderate to severe alopecia areata should be considered a medical indication for systemic treatment. Currently, the only two EMA‐approved medications for alopecia areata are baricitinib (JAK 1/2 inhibitor) for adults and ritlecitinib (JAK 3/TEC inhibitor) for individuals aged 12 and older. Both are EMA‐approved for patients with severe alopecia areata. Other systemic medications used off‐label in alopecia areata include glucocorticosteroids, cyclosporine, methotrexate and azathioprine. Oral minoxidil is considered an adjuvant therapy with limited data confirming its possible efficacy. This consensus statement is to outline a systemic treatment algorithm for alopecia areata, indications for systemic treatment, available therapeutic options, their efficacy and safety, as well as the duration of the therapy.

show abstract

“…Additional tests also include those needed to exclude contraindications for the intended therapy. 13…”

Section: Agnosis a N D Base Li N E E X A M I Nationmentioning

confidence: 99%

Section: Cyclosporinementioning

confidence: 99%

Section: Azathioprinementioning

confidence: 99%

Section: Treatment Duration and Follow-upmentioning

confidence: 99%

See 2 more Smart Citations

European expert consensus statement on the systemic treatment of alopecia areata

Rudnicka,

Arenbergerova,

Grimalt

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…If anyone's family history has pruritic skin disease or asthma, allergic rhinitis, food allergies etc. are triggering factors [3] . Atopic dermatitis (AD) pathophysiology is either primary irritants like acids, alkalis, etc.…”

Section: Introductionmentioning

confidence: 99%

Homoeopathic management can cure non-communicable chronic Atopic Eczema (Dermatitis) with Sleeplessness, indigestion and depression: A case report upon neurodermatitis

Das¹,

Sarkar²,

Sabud³

2022

Int. J. Homoeopathic Sci.

View full text Add to dashboard Cite

Atopic dermatitis (AD) also known as atopic eczema is a chronic inflammatory dermatosis characterised by pruritus & chronicity due to antigen-antibody reaction manifesting on skin conditions associated with intra & intercellular Creaked & oedema. The prevalence of AD is 20% (5%-30% in the paediatric and 1%-10% in the adult population) worldwide; 3%-6% in Asian-Pacific countries, Eastern Mediterranean region, and India. A Hindu 45 years female chief complains were hot, dry skin in all over the body, dry eruption with a small brown-black scab in both palms, lower abdomen & soles. Ulcer formation corrodes & becomes deeper like punched-out edges with a tendency to penetrate and tenacious exudation without spreading in circumference & she suffered for 3-4 years. We evaluated this case on SCORAD Index & Assessment by Modified Naranjo Criteria Score. This case report highlighted the mental symptoms followed by physical & particular symptoms. The study was clearly shown the good scope of homoeopathic remedies work for treatment of Atopic Eczema (Dermatitis) along with mental complaints like, depression, anxiety, ill humour, low spirit, sleeplessness etc. There have some limitations to Atopic Eczema (Dermatitis) like, Sever bronchial asthma, hay fever, Alzheimer's disease, Multiple Sclerosis etc.

show abstract

Assessment and Management of Atopic Dermatitis in Primary Care Settings

Najlaa Mohammad Alsudairy,

Shorooq Ahmed Hamzi,

Eman Ahmed M Alrashed

et al. 2023

J. Adv. Zool.

View full text Add to dashboard Cite

An increasingly common chronic inflammatory skin condition is atopic dermatitis (AD). It exhibits severe itching as well as recurring eczematous lesions. New difficulties for treatment selection and approach occur with the expansion of available therapy alternatives for healthcare professionals and patients. The article highlights recent developments in scientific research on atopic dermatitis diagnosis and assessment that have led to the identification of novel therapeutic targets and the development of targeted therapies, both of which have the potential to completely change the way AD is treated, particularly in a primary care setting.

show abstract

National Saudi Consensus Statement on the Management of Atopic Dermatitis (2021)

Cited by 7 publications

References 115 publications

European expert consensus statement on the systemic treatment of alopecia areata

European expert consensus statement on the systemic treatment of alopecia areata

Homoeopathic management can cure non-communicable chronic Atopic Eczema (Dermatitis) with Sleeplessness, indigestion and depression: A case report upon neurodermatitis

Assessment and Management of Atopic Dermatitis in Primary Care Settings

Contact Info

Product

Resources

About